Venmax Drugs & Pharmaceuticals Ltd (531015)
🎯 Key Takeaways
- Venmax Drugs & Pharmaceuticals Ltd is in a critical turnaround phase, transitioning from financial distress to potential stabilization, marked by leadership changes and governance updates. The company has shown early signs of operational recovery with sequential revenue improvement and a shift toward profitability, supported by new management appointments and shareholder restructuring.
- Revenue declined 37.1% QoQ to ₹2 in Q1FY27.
- ⚠️ The company continues to report negative ROE and ROCE, highlighting persistent profitability challenges despite improving operational metrics. High pr
📖 The Story
Venmax Drugs & Pharmaceuticals Ltd is in a critical turnaround phase, transitioning from financial distress to potential stabilization, marked by leadership changes and governance updates. The company has shown early signs of operational recovery with sequential revenue improvement and a shift toward profitability, supported by new management appointments and shareholder restructuring.
📰 What's Happening
In August 2026, the board approved the 2025-26 Directors Report and announced the 37th AGM scheduled for September 26, 2026, with e-voting from September 23-25. A key development was the designation of Venkata Rao Sadhanala as Managing Director effective March 11, 2026, signaling leadership stabilization. The AGM will focus on shareholder approval of this appointment and new director nominations, indicating efforts to strengthen governance post-restructuring. These governance updates suggest management is prioritizing transparency and investor confidence after a period of financial volatility.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 1 | 2 | 4 | 2 |
| Operating Profit | 0 | -0 | 0 | 0 |
| OPM % | 3.8% | -1.9% | 0.3% | 4.8% |
| Net Profit | 0 | 0 | 0 | 0 |
| EPS | ₹0.05 | ₹0.05 | ₹0.21 | ₹0.10 |
Revenue has shown sequential improvement, rising from ₹1 crore in September 2025 to ₹4 crore in March 2026, with operating profit turning positive at ₹0.21 crore in the latest quarter. Operating margins improved from -1.9% to 4.8% over the same period, reflecting cost discipline or volume gains. Despite this, net profit remains volatile due to scale, but the trend in operating performance suggests management’s operational interventions are beginning to yield results, even if profitability is still emerging.
🔮 Management Outlook & What's Next
Management has not provided explicit forward guidance on revenue or profitability in the available filings. However, the upcoming 37th AGM on September 26, 2026, will be a key event where shareholders will vote on the new Managing Director appointment and board composition, which may set the tone for future strategic direction. The absence of formal guidance suggests the company is in a stabilization phase, focusing on governance and operational consolidation rather than expansion.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2026 | Mar 2026 | Mar 2026 | Mar 2027 |
|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 8 | 12 | 12 |
| Reserves | -6 | -1 | 1 | 3 | 3 |
| Borrowings | 0 | 0 | 3 | 0 | 0 |
| Total Liabilities | 5 | 7 | 14 | 16 | 17 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 5 | 7 | 14 | 16 | 17 |
The balance sheet shows a strengthening financial position, with equity increasing to ₹12 crore and reserves at ₹3 crore as of March 2026, while borrowings remain zero. Total assets grew to ₹17 crore, indicating modest asset base expansion without leverage. This suggests the company is not over-investing or taking on debt, but rather building capital reserves organically, likely from retained earnings or revaluation, supporting a conservative and sustainable growth trajectory.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 |
|---|---|
| Operating | -2 |
| Investing | 0 |
| Financing | +5 |
| Net Cash Flow | +2 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 23.1% | 15.1% | 13.8% | 10.5% |
| FII | 0.0% | 0.0% | 0.0% | 0.0% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% |
| Public | 65.4% | 64.3% | 66.3% | 74.3% |
| # Shareholders | 6,764 | 6,815 | 6,802 | 6,865 |
Promoter holding has declined significantly from 23.14% in Q2FY26 to 10.46% in Q1FY27, while public shareholding rose from 65.36% to 74.34%, reflecting retail investor interest and possible exit of early promoters. However, FII and DII holdings remain negligible at 0%, indicating limited institutional interest. The rising number of shareholders (6,865) suggests growing retail participation, but the lack of institutional accumulation may signal skepticism about near-term growth prospects.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.63 L Cr | 38.3 | 18.7% | 14.6% | 0.05 |
| DIVISLAB | 2.43 L Cr | 83.2 | 23.0% | 17.4% | 0.00 |
| TORNTPHARM | 1.89 L Cr | 79.1 | 15.1% | 25.7% | 1.76 |
| ZYDUSLIFE | 1.16 L Cr | 25.9 | 16.8% | 16.6% | 0.43 |
| CIPLA | 1.15 L Cr | 34.0 | 13.2% | 9.8% | 0.01 |
| LAURUSLABS | 1.00 L Cr | 91.8 | 20.8% | 20.6% | 0.45 |
| LUPIN | 98,305 | 17.4 | 27.9% | 24.7% | 0.26 |
| DRREDDY | 97,741 | 30.3 | 10.1% | 8.4% | 0.17 |
| MANKIND | 97,467 | 47.7 | 13.9% | 12.7% | 0.38 |
| AUROPHARMA | 96,836 | 26.3 | 12.8% | 9.8% | 0.20 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
The company continues to report negative ROE and ROCE, highlighting persistent profitability challenges despite improving operational metrics. High promoter dilution and low institutional interest raise concerns about confidence in long-term viability. Additionally, the absence of forward guidance and reliance on quarterly operational fluctuations suggest limited visibility into a sustainable earnings recovery, making future performance highly uncertain.
📋 Recent Filings
-
🔴 annual report 1 September 2026Venmax Drugs & Pharmaceuticals Limited submitted its 2025-26 Annual Report to BSE on September 1, 2026, detailing the 37th AGM scheduled for September...
-
🟡 Board Meeting 31 August 2026Venmax Drugs & Pharmaceuticals announced board approval of the 2025-26 Directors Report, Secretarial Audit, and 37th AGM scheduled for September 26, 2...
🧠 Analyst's Read
Venmax Drugs & Pharmaceuticals is undergoing a fragile recovery, with early signs of operational improvement but no clear path to profitability yet. Investors should monitor shareholder approval of the new Managing Director at the upcoming AGM and any future operational updates that clarify revenue sustainability and margin trajectory.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts for your stocks — summarized by AI daily
Set up your AI Radar — pick stocks, get daily email summaries of new filings.
Set up AI Radar — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd